# Tropic

**Source:** https://geo.sig.ai/brands/tropic  
**Vertical:** AgTech  
**Subcategory:** Crop Biotech (Gene Editing)  
**Tier:** Challenger  
**Website:** tropic.bio  
**Last Updated:** 2026-04-14

## Summary

Crop biotech company behind first new banana varieties in 75 years; raised $105M oversubscribed Series C co-led by Forbion and Corteva in March 2026; non-browning banana named TIME Best Invention 2025; demand exceeds supply.

## Company Overview

Tropic is a crop biotechnology company that launched the first new banana varieties in over 75 years in 2025, including a non-browning banana named a TIME Best Invention of 2025. The company raised $105 million in oversubscribed Series C financing in March 2026, co-led by Forbion and Corteva — one of the largest crop biotech raises of the year. Demand for Tropic's non-browning banana already exceeds supply ahead of broader commercial deployment in 2027.

Tropic's gene-editing platform works with crops that face existential threats: the Cavendish banana (which accounts for 99% of global exports) is facing devastation from Fusarium TR4 fungus, and Tropic is developing TR4-resistant varieties that could prevent a banana supply crisis. The company is simultaneously working on climate-resilient rice, targeting the staple crop that feeds half the world's population and faces increasing drought and flood stress.

The Corteva co-lead is particularly significant: Corteva is one of the world's largest agricultural seed companies, and its investment signals both technical validation of Tropic's platform and a potential distribution pathway for commercial seed deployment. Tropic's pipeline addresses multiple interrelated threats — disease, climate, and consumer preference — using a single gene-editing capability that can be applied across species.

## Frequently Asked Questions

### What does Tropic do?
Gene-editing platform for crop improvement — launched first new banana varieties in 75+ years including non-browning and TR4-resistant strains, plus climate-resilient rice.

### How much has Tropic raised?
$105M oversubscribed Series C in March 2026, co-led by Forbion and Corteva.

### What is the TR4 banana problem?
Fusarium TR4 fungus is devastating Cavendish banana plantations globally. Tropic's TR4-resistant varieties could prevent a catastrophic supply collapse in the most-consumed banana variety.

### What is the non-browning banana?
A gene-edited banana variety that doesn't brown after being cut or peeled — named a TIME Best Invention of 2025. Consumer demand already exceeds Tropic's supply.

### What other crops is Tropic working on beyond bananas and rice?
Tropic has expanded its gene-editing pipeline to sugar cane, targeting disease resistance and improved sucrose yield to address the threat of disease epidemics in a crop worth over $30B annually to global commodity markets.

### How does Tropic's gene editing differ from GMO modification?
Tropic uses CRISPR and proprietary gene-editing tools to modify existing plant genes without introducing foreign DNA from other species, which in many jurisdictions — including the US and UK — is regulated differently than transgenic GMO crops.

### What is Tropic's commercial model?
Tropic sells improved varieties directly to banana plantation operators and licensing its gene-editing platform to seed companies and agricultural partners, creating dual revenue streams from both variety sales and platform royalties.

### Is Tropic publicly traded?
No, Tropic is a privately held agricultural biotechnology company headquartered in Norwich, UK, with its most recent Series C funding from Forbion, Corteva, and other agricultural and climate investors.

## Tags

agriculture, saas, b2b, startup

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*